Editorial Comment to Effect of optimal neoadjuvant chemotherapy on oncological outcomes of locally advanced bladder cancer with laparoscopic radical cystectomy: A matched‐pair analysis in a multicenter cohort

Abstract

rate for pathological response to neoadjuvant chemotherapy and post-cystectomy survival of bladder urothelial cancer. Jpn. J. Clin. Oncol. 2016; 46: 560–7. 26 Zargar H, Espiritu PN, Fairey AS et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Euro. Urol. 2015; 67: 241–9. 27 Bhindi B, Frank I, Mason RJ et al. Oncologic outcomes for patients with residual cancer at cystectomy following neoadjuvant chemotherapy: a pathologic stage-matched analysis. Eur. Urol. 2017; 72: 660–4. 28 Sternberg CN, Skoneczna I, Kerst JM et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol. 2015; 16: 76–86. 29 Galsky MD, Stensland KD, Moshier E et al. Effectiveness of adjuvant chemotherapy for locally advanced bladder cancer. J. Clin. Oncol. 2016; 34: 825–32.